Introduction

Rare hereditary diseases, often caused by mutations in single genes, collectively affect millions of people worldwide, yet their diagnosis and molecular understanding remain major medical challenges. Traditional genetic testing methods, such as linkage analysis and targeted gene sequencing, have provided valuable insights but are limited by their inability to capture the full spectrum of genomic variation. Whole-Genome Sequencing (WGS) has revolutionized the field of medical genetics by enabling comprehensive analysis of both coding and non-coding regions of the genome. Unlike whole-exome sequencing, which focuses solely on protein-coding genes, WGS examines every base pair, offering unparalleled resolution for identifying structural variants, copy number variations, and rare single-nucleotide mutations. This genome-wide approach is especially powerful for deciphering the complex genetic architecture of rare hereditary diseases that often escape detection through conventional diagnostic methods [1].

Description

Whole-genome sequencing provides an unbiased and detailed view of the human genome, capturing variants that other methods may overlook. By analyzing both the nuclear and mitochondrial genomes, WGS allows researchers to detect Single-Nucleotide Variants (SNVs), insertions, deletions, structural rearrangements, and even repeat expansions that can disrupt gene function. In rare hereditary diseases such as cystic fibrosis, Duchenne muscular dystrophy, and certain forms of intellectual disability, WGS has helped identify novel disease-causing mutations that were previously undetectable. Advanced bioinformatics tools now play a vital role in processing the enormous amount of sequencing data generated, allowing scientists to annotate, filter, and interpret variants based on clinical significance [2].

Moreover, long-read sequencing technologies such as Oxford Nanopore and PacBio have enhanced our ability to detect complex structural variants and repetitive regions that are difficult to resolve using short-read platforms. These advancements have greatly improved diagnostic yield and expanded our understanding of genetic heterogeneity in rare disorders. Beyond variant detection, WGS enables functional interpretation of mutations through integration with transcriptomic and epigenomic data. Genome-wide sequencing can identify mutations in regulatory regions such as promoters, enhancers, and non-coding RNAs that influence gene expression and disease manifestation. Comparative analyses of affected and unaffected family members often reveal de novo mutations or compound heterozygous variants that underlie disease phenotypes [3].

Furthermore, the establishment of global genomic databases and biobanks, such as the 100,000 Genomes Project in the UK and the Genome India Initiative, has fostered international collaboration for rare disease discovery. Ethical considerations remain central, particularly concerning incidental findings, privacy, and data sharing. Nevertheless, as computational power and clinical interpretation frameworks evolve, the integration of WGS into routine healthcare promises earlier and more accurate diagnoses, paving the way for personalized therapies and genetic counselling tailored to each patientâ??s unique genomic profile [4,5].

Conclusion

In conclusion, whole-genome sequencing represents a transformative tool in the study and diagnosis of rare hereditary diseases. By enabling comprehensive detection of both known and novel variants, WGS bridges the gap between undiagnosed genetic disorders and precision medicine. Its ability to uncover hidden mutations in both coding and non-coding regions provides critical insights into disease mechanisms and inheritance patterns. While challenges related to data interpretation, ethical oversight, and clinical implementation persist, the continued refinement of sequencing technologies and bioinformatics pipelines will further enhance diagnostic accuracy and accessibility.

Acknowledgement

None

Conflict of Interest

None

References

1. Al-Zayed Z, Al-Rijjal RA, Al-Ghofaili L, BinEssa HA, Pant R, et al. (2021) Mutation spectrum of EXT1 and EXT2 in the Saudi patients with hereditary multiple exostoses. Orphanet J Rare Dis 16: 1–11

Google Scholar  Cross Ref  Indexed at

2. Pedrini E, Jennes I, Tremosini M, Milanesi A, Mordenti M, et al. (2011) Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: Identification of “protective” and “risk” factors. J Bone Jt Surg Am 93: 2294–2302

Google Scholar  Cross Ref  Indexed at

3. Sarrión P, Sangorrin A, Urreizti R, Delgado MA, Artuch R, et al. (2013) Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas. Sci Rep 3: 1346

Google Scholar  Cross Ref  Indexed at

4. Xian C, Zhu M, Nong T, Li Y, Xie X, et al. (2021) A novel mutation in EXT2 caused hereditary multiple exostoses through reducing the synthesis of heparan sulfate. Genet Mol Biol 44: e20200334

Google Scholar  Cross Ref  Indexed at

5. Senay C, Lind T, Muguruma K, Tone Y, Kitagawa H, et al. (2000) The EXT1/EXT2 tumor suppressors: Catalytic activities and role in heparan sulfate biosynthesis. EMBO Rep 1: 282–286

Google Scholar  Cross Ref  Indexed at